Skip to main content

BrainsWay Deep TMS™:
The Most Innovative Neuromodulation Platform

Built to Help You Scale Faster

Screenshot 2026-05-08 124415
Clinical Efficacy

The broadest FDA-cleared with 9 indications, most validated Deep TMS, and extensive real-world clinical data across psychiatric conditions.

Acceleration + Outcomes

FDA-cleared accelerated protocols. Shorter treatment timelines and faster paths to remission — for patients and practices alike.

ROI & Throughput

Higher patient throughput, faster reimbursement cycles, stronger cash flow — improving clinical outcomes and clinic economics simultaneously.

Discover how you can add DEEP TMS to your practice

Connect with our team to discuss Deep TMS for your practice.

The Deeper, Broader Advantage of Deep TMS

BrainsWay’s patented H-coil technology delivers unmatched clinical depth and efficacy, overcoming the targeting limitations of first-generation systems.

Deeper, Broader Targeting:  Patented H-coils reach vital neural networks deeper than traditional, flat figure-8 coils to maximize neuron activation.
Proven Clinical Superiority: Achieved a 67% response rate compared to just 44% with first-generation TMS systems in a randomized trial.
Better Operator Experience: A smart touchscreen interface guides your staff through quick setup and motor threshold determination. 
Enhanced Patient Comfort: The cushioned, cooled helmet allows slight mobility during brief sessions without compromising treatment accuracy.

Expand Your Treatment Offerings

Future-proof your behavioral health practice. BrainsWay has nine FDA clearances backed by peer-reviewed evidence across a comprehensive range of treatments, including:

Major Depressive Disorder (MDD)

Indicated for treating depression and decreasing comorbid anxiety symptoms. Real-world data shows an approximate 2 in 3 remission rate for patients completing a standard 20-minute protocol.

Obsessive-Compulsive Disorder (OCD)

The first noninvasive device FDA-cleared as an adjunct treatment for severe, refractory OCD, directly targeting deeper cortical structures.

Smoking Addiction

FDA-cleared as an aid in short-term smoking cessation, utilizing specialized targeting to modulate the brain's salience network.